27-Mar-2026
Hutchmed Expands Oncology Pipeline With New First-in-Human Solid Tumor Trial
TipRanks (Fri, 27-Mar 12:36 PM ET)
HUTCHMED (China) (HCM) Gets a Buy from GF Securities
TipRanks (Tue, 24-Mar 3:05 AM ET)
Globe Newswire (Sun, 22-Mar 8:00 PM ET)
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK in China
Globe Newswire (Mon, 9-Mar 5:30 AM ET)
Globe Newswire (Fri, 6-Mar 3:30 AM ET)
HUTCHMED Reports 2025 Full Year Results and Business Updates
Globe Newswire (Thu, 5-Mar 6:00 AM ET)
Globe Newswire (Wed, 4-Mar 3:30 AM ET)
HUTCHMED to Announce 2025 Final Results
Globe Newswire (Fri, 6-Feb 3:30 AM ET)
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Globe Newswire (Tue, 13-Jan 11:00 PM ET)
Globe Newswire (Tue, 6-Jan 7:00 PM ET)
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Hutchmed (China) Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol HCM.
As of March 27, 2026, HCM stock price declined to $13.81 with 31,551 million shares trading.
HCM has a beta of 0.53, meaning it tends to be less sensitive to market movements. HCM has a correlation of 0.05 to the broad based SPY ETF.
HCM has a market cap of $2.37 billion. This is considered a Mid Cap stock.
Last quarter Hutchmed (China) Limited - American Depositary Shares reported $549 million in Revenue and $2.62 earnings per share. This fell short of revenue expectation by $-43 million and exceeded earnings estimates by $1.19.
In the last 3 years, HCM traded as high as $21.92 and as low as $10.68.
The top ETF exchange traded funds that HCM belongs to (by Net Assets): SPDW, CANC, DFEM, NSI, DFAX.
HCM has underperformed the market in the last year with a return of -9.5%, while SPY returned +13.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HCM shares. However, HCM has outperformed the market in the last 3 month and 2 week periods, returning +0.3% and -1.2%, while SPY returned -7.9% and -4.0%, respectively. This indicates HCM has been having a stronger performance recently.
HCM support price is $13.82 and resistance is $14.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCM shares will trade within this expected range on the day.